Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Kirloskar Ferrous Industries Reports 11% Net Profit Growth in Q2 FY26

Industrial Goods/Services

|

Updated on 06 Nov 2025, 12:37 pm

Whalesbook Logo

Reviewed By

Akshat Lakshkar | Whalesbook News Team

Short Description:

Kirloskar Ferrous Industries Ltd announced its second-quarter results for the period ending September 2025, showing an 11% year-on-year increase in net profit to ₹86.2 crore. Revenue from operations grew 5.3% to ₹1,755 crore, with EBITDA rising 11% to ₹215.3 crore and margins improving to 12.3%.
Kirloskar Ferrous Industries Reports 11% Net Profit Growth in Q2 FY26

▶

Stocks Mentioned:

Kirloskar Ferrous Industries Ltd

Detailed Coverage:

Kirloskar Ferrous Industries Ltd has reported its financial results for the second quarter of the fiscal year ending September 30, 2025. The company achieved a net profit of ₹86.2 crore, marking an 11% increase compared to the ₹77.6 crore reported in the same quarter of the previous year. Revenue from operations also saw a positive trend, growing by 5.3% to ₹1,755 crore, up from ₹1,666 crore in the prior year's corresponding period. Furthermore, the company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose by 11% to ₹215.3 crore, from ₹194 crore a year ago. This growth was accompanied by an improvement in the EBITDA margin, which increased to 12.3% from 11.6% in the previous year.

Founded in 1991, Kirloskar Ferrous Industries is a prominent Indian manufacturer specializing in pig iron and grey iron castings, serving sectors such as automotive and engines. It is a part of the established Kirloskar Group.

Impact: These financial results indicate a healthy operational performance and growth for Kirloskar Ferrous Industries. The increase in profit, revenue, and margins suggests effective business management and market demand, which could lead to a positive reception from investors and potentially influence the company's stock performance. Impact Rating: 7/10.

Difficult Terms: - Net Profit: The profit remaining after all expenses, taxes, and costs have been deducted from the total revenue. - Revenue from Operations: The income generated from a company's core business activities. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): A measure of a company's operating performance before accounting for financing costs, taxes, and non-cash expenses. - EBITDA Margin: Calculated as EBITDA divided by Revenue, it shows the profitability of a company's core business operations as a percentage of its revenue. - Year-on-year (YoY): A comparison of financial data from one period to the same period in the previous year to understand trends.


SEBI/Exchange Sector

SEBI cautions investors against unregulated 'Digital Gold' products, highlights risks

SEBI cautions investors against unregulated 'Digital Gold' products, highlights risks

NSDL Lists: India's Dominant Depository Steps Out of Shadows as 'Banker of Big Money'

NSDL Lists: India's Dominant Depository Steps Out of Shadows as 'Banker of Big Money'

SEBI cautions investors against unregulated 'Digital Gold' products, highlights risks

SEBI cautions investors against unregulated 'Digital Gold' products, highlights risks

NSDL Lists: India's Dominant Depository Steps Out of Shadows as 'Banker of Big Money'

NSDL Lists: India's Dominant Depository Steps Out of Shadows as 'Banker of Big Money'


Healthcare/Biotech Sector

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

India Mandates Stricter Pharma Manufacturing Standards by January Amidst Child Death Concerns

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

SMS Pharmaceuticals Reports 76.4% Profit Jump on Strong Revenue Growth

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions

Poly Medicure Reports 5% Rise in Q2 FY26 Net Profit, Driven by Domestic Growth and Strategic Acquisitions